Biomm S.A. (BVMF:BIOM3)

Market Cap	1.05B -18.3%
Revenue (ttm)	269.30M +88.4%
Net Income	-6.69M
EPS	-0.05
Shares Out	136.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,700
Average Volume	79,830
Open	7.70
Previous Close	7.84
Day's Range	7.65 - 7.83
52-Week Range	5.75 - 10.66
Beta	0.82
RSI	60.23
Earnings Date	May 15, 2026

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a Human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; and Lifepen G, a reusable insulin injection pen. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the prophylaxis and treatment ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 130
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIOM3

Financial Performance

In 2025, Biomm's revenue was 269.30 million, an increase of 88.45% compared to the previous year's 142.91 million. Losses were -6.69 million, -91.34% less than in 2024.